152 related articles for article (PubMed ID: 36107485)
1. Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study.
de Castro Silva I; Bianchi A; Deshpande NU; Sharma P; Mehra S; Garrido VT; Saigh SJ; England J; Hosein PJ; Kwon D; Merchant NB; Datta J
Elife; 2022 Sep; 11():. PubMed ID: 36107485
[TBL] [Abstract][Full Text] [Related]
2. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
3. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
[TBL] [Abstract][Full Text] [Related]
4. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
5. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
He P; Yang JW; Yang VW; Bialkowska AB
Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
[TBL] [Abstract][Full Text] [Related]
6. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
7. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
8. Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer.
Bianchi A; De Castro Silva I; Deshpande NU; Singh S; Mehra S; Garrido VT; Guo X; Nivelo LA; Kolonias DS; Saigh SJ; Wieder E; Rafie CI; Dosch AR; Zhou Z; Umland O; Amirian H; Ogobuiro IC; Zhang J; Ban Y; Shiau C; Nagathihalli NS; Montgomery EA; Hwang WL; Brambilla R; Komanduri K; Villarino AV; Toska E; Stanger BZ; Gabrilovich DI; Merchant NB; Datta J
Cancer Discov; 2023 Jun; 13(6):1428-1453. PubMed ID: 36946782
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
Uddin MH; Al-Hallak MN; Khan HY; Aboukameel A; Li Y; Bannoura SF; Dyson G; Kim S; Mzannar Y; Azar I; Odisho T; Mohamed A; Landesman Y; Kim S; Beydoun R; Mohammad RM; Philip PA; Shields AF; Azmi AS
Clin Transl Med; 2023 Dec; 13(12):e1513. PubMed ID: 38131168
[TBL] [Abstract][Full Text] [Related]
10. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
11. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
12. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance.
Ajina R; Malchiodi ZX; Fitzgerald AA; Zuo A; Wang S; Moussa M; Cooper CJ; Shen Y; Johnson QR; Parks JM; Smith JC; Catalfamo M; Fertig EJ; Jablonski SA; Weiner LM
Cancer Immunol Res; 2021 Apr; 9(4):386-400. PubMed ID: 33509790
[TBL] [Abstract][Full Text] [Related]
13. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
[TBL] [Abstract][Full Text] [Related]
14. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression.
Ijichi H; Chytil A; Gorska AE; Aakre ME; Fujitani Y; Fujitani S; Wright CV; Moses HL
Genes Dev; 2006 Nov; 20(22):3147-60. PubMed ID: 17114585
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
16. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
[TBL] [Abstract][Full Text] [Related]
17. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.
Long KB; Tooker G; Tooker E; Luque SL; Lee JW; Pan X; Beatty GL
Mol Cancer Ther; 2017 Sep; 16(9):1898-1908. PubMed ID: 28611107
[TBL] [Abstract][Full Text] [Related]
18. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
[TBL] [Abstract][Full Text] [Related]
19. Moderate alcohol intake promotes pancreatic ductal adenocarcinoma development in mice expressing oncogenic Kras.
Asahina K; Balog S; Hwang E; Moon E; Wan E; Skrypek K; Chen Y; Fernandez J; Romo J; Yang Q; Lai K; French SW; Tsukamoto H
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G265-G276. PubMed ID: 31760766
[No Abstract] [Full Text] [Related]
20. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma.
Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL
Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
